After getting the cold shoulder from regulators over its filing for CAR-T candidate ide-cel earlier this week, Bristol Myers Squibb at least has good news now for one of the products it acquired through its $74 billion Celgene buyout.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,